Ferroptosis is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Ferroptosis is a regulated form of non-apoptotic cell death characterized by iron-dependent lipid peroxidation and distinct from apoptosis, necroptosis, and [1]
autophagy-dependent death. First formally described in 2012 by Dixon et al., ferroptosis has rapidly emerged as a critical mechanism of neuronal death in Alzheimer's disease, [2]
Parkinson's disease, Huntington's disease, and ALS, driven by the brain's unique vulnerability to iron dysregulation and lipid peroxidation[3][1:1]. [4]
The brain is particularly susceptible to ferroptosis due to its high iron content (the brain contains ~60 mg of iron in the adult), abundance of polyunsaturated fatty acid (PUFA)-rich membranes (comprising >30% of brain lipids), high oxidative metabolism (consuming ~20% of body oxygen), and limited regenerative capacity. Iron accumulation in specific brain regions is now recognized as a hallmark of multiple neurodegenerative diseases, and ferroptosis represents a mechanistic link between metal dyshomeostasis, oxidative stress, and neuronal death[2:1]. [5]
Ferroptosis execution requires three converging elements: iron availability, PUFA-containing phospholipids, and failure of antioxidant defense systems. [6]
Iron-dependent lipid peroxidation cascade: [7]
| Protein/System | Role | Effect on Ferroptosis | [8]
|---------------|------|----------------------| [9]
| System Xc⁻ (SLC7A11/SLC3A2) | Cystine/glutamate antiporter | Imports cystine for glutathione synthesis; inhibition (by erastin) promotes ferroptosis | [10]
| GPX4 | Glutathione peroxidase 4 | Reduces lipid hydroperoxides (LOOH) to alcohols (LOH); the central ferroptosis suppressor | [11]
| FSP1 (AIFM2) | CoQ10-dependent oxidoreductase | GPX4-independent ferroptosis defense; reduces CoQ10 to CoQ10H₂ which traps lipid radicals | [12]
| DHODH | Dihydroorotate dehydrogenase | Mitochondrial CoQ10 reduction; third anti-ferroptotic pathway | [13]
| GCH1-BH4 | GTP cyclohydrolase 1 / tetrahydrobiopterin | BH4 acts as radical-trapping antioxidant; fourth independent ferroptosis defense | [14]
| Ferritin (FTH1/FTL) | Iron storage | Sequesters labile iron in safe ferric form; ferritinophagy (NCOA4-mediated) releases iron | [15]
| ACSL4 | Acyl-CoA synthetase long-chain 4 | Enriches membranes with PUFA-PE; essential for ferroptosis execution | [16]
| LPCAT3 | Lysophosphatidylcholine acyltransferase 3 | Inserts PUFAs into phospholipids; promotes ferroptosis sensitivity |
| Nrf2 (NFE2L2) | Transcription factor | Master regulator inducing GPX4, SLC7A11, FTH1, HO-1; major ferroptosis suppressor |
| TFRC (TfR1) | Transferrin receptor | Iron uptake; high expression sensitizes cells; recently identified as a ferroptosis marker |
| 7-DHC | 7-Dehydrocholesterol | Endogenous ferroptosis suppressor identified in 2024; traps lipid radicals |
This is the canonical ferroptosis defense pathway, and its disruption is the most common trigger for ferroptosis:
Recent discoveries have revealed that cells possess multiple independent ferroptosis defense systems:
Multiple lines of evidence implicate ferroptosis in AD pathogenesis[5:1][6:1]:
Iron accumulation:
Lipid peroxidation:
GPX4 dysfunction:
PD has among the strongest evidence for ferroptosis involvement in any neurodegenerative disease:
Iron chelators:
| Agent | Route | BBB Penetration | Clinical Status | Notes |
|---|---|---|---|---|
| Deferiprone (DFP) | Oral | Good | Phase II completed (PD); Phase II planned (AD) | FAIRPARK-II: paradoxical worsening in early, untreated PD[7:2]; timing and concurrent dopaminergic Rx may be critical |
| Deferoxamine (DFO) | IV/SC | Poor | Preclinical for neurodegeneration | Potent chelator; limited by poor BBB penetration; intranasal delivery explored |
| Deferasirox | Oral | Moderate | Preclinical | Used clinically for iron overload; neuroprotective in models |
| PBT2 (clioquinol analog) | Oral | Good | Phase II completed (AD, HD) | Metal-protein attenuating compound; modest signal in HD |
Lipophilic radical-trapping antioxidants (RTAs):
GPX4 activators and GSH restorers:
Nrf2 activators (upstream ferroptosis defense):
2025 research demonstrates that eight weeks of aerobic exercise significantly activates the System Xc⁻/GPX4 signaling axis in the prefrontal cortex of AD mice, upregulates ferritin light chain (FTL), downregulates 4-HNE, inhibits ferroptosis, and ameliorates cognitive deficits — providing mechanistic evidence for exercise-mediated neuroprotection against ferroptosis[8:1].
Emerging evidence suggests that stem cell derivatives (exosomes, conditioned media, secretome) from mesenchymal stem cells (MSCs) and neural stem cells can inhibit ferroptosis by restoring GPX4 expression, reducing iron overload, and delivering anti-ferroptotic microRNAs — representing a cell-free therapeutic approach[9:1].
| Marker | Method | What It Detects |
|---|---|---|
| Lipid peroxidation | C11-BODIPY 581/591, 4-HNE immunostaining, MDA assay, TBARS | Active lipid ROS and peroxidation damage products |
| Iron | Prussian blue/Perl's staining, calcein-AM quenching, ICP-MS | Labile and total cellular iron |
| GPX4 | Western blot, immunohistochemistry, activity assay | GPX4 protein levels and enzymatic function |
| GSH/GSSG ratio | ThiolTracker, Ellman's reagent, HPLC | Reduced glutathione levels and redox status |
| Gene signatures | RNA-seq, qPCR panels | PTGS2↑, CHAC1↑, TFRC↑, GPX4↓, SLC7A11↓ |
| Electron microscopy | Transmission EM | Shrunken mitochondria with increased membrane density, reduced cristae (pathognomonic) |
| ACSL4 | Western blot, IHC | PUFA-PE biosynthetic enzyme; ferroptosis sensitivity marker |
An important emerging concept is the crosstalk between ferroptosis and neuroinflammation:
The study of Ferroptosis has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Dixon SJ, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149(5):1060-1072. DOI. 2012. ↩︎ ↩︎
Guo C, et al. Iron homeostasis and neurodegeneration in the ageing brain: insight into ferroptosis pathways. Ageing Res Rev. 2024;104:102575. ScienceDirect. 2024. ↩︎ ↩︎
Stockwell BR, et al. Ferroptosis: a regulated cell death nexus linking metabolism, redox biology, and disease. Cell. 2017;171(2):273-285. PubMed. 2017. ↩︎
Freitas FP, et al. 7-Dehydrocholesterol is an endogenous suppressor of ferroptosis. Science. 2024. DOI. 2024. ↩︎ ↩︎
Zhang Y, et al. The role of ferroptosis in neurodegenerative diseases. Mol Neurobiol. 2021;58(4):1965-1978. PubMed. 2021. ↩︎ ↩︎
Thorwald MA, et al. Iron-associated lipid peroxidation in Alzheimer's Disease is increased in lipid rafts with decreased ferroptosis suppressors, tested by chelation in mice. Alzheimers Dement. 2025. DOI. 2025. ↩︎ ↩︎ ↩︎
Devos D, et al. Trial of deferiprone in Parkinson''s Disease. N Engl J Med. 2022;387(22):2045-2055. DOI: 10.1056/NEJMoa2209254. 2022. ↩︎ ↩︎ ↩︎
Chen L, et al. Ferroptosis in neurodegenerative diseases: potential mechanisms of exercise intervention. Front Cell Dev Biol. 2025;13:1622544. DOI. 2025. ↩︎ ↩︎
Li Y, et al. Ferroptosis in neurodegenerative diseases: mechanisms and therapeutic potential of stem cell derivatives. Stem Cell Res Ther. 2025;16:156. PMC. 2025. ↩︎ ↩︎
Zhou Y, et al. Targeting ferroptosis for neuroprotection: potential therapeutic avenues in neurodegenerative and neuropsychiatric diseases. Front Physiol. 2025;16:1641323. DOI: 10.3389/fphys.2025.1641323. 2025. ↩︎ ↩︎
Meng H, et al. Ferroptosis and iron homeostasis: molecular mechanisms and neurodegenerative disease implications. Antioxidants. 2024;14(5):527. PMC. 2024. ↩︎
Li J, et al. A critical appraisal of ferroptosis in Alzheimer''s and Parkinson''s Disease: new insights into emerging mechanisms and therapeutic targets. Front Aging Neurosci. 2024;16:1475934. PubMed. 2024. ↩︎
Deng X, et al. The role of ferroptosis in neurodegenerative diseases. Front Cell Neurosci. 2024;18:1475934. PMC. 2024. ↩︎
Conrad M, et al. Regulation of lipid peroxidation and ferroptosis in diverse species. Genes Dev. 2018. ↩︎
Ayton S, et al. Brain iron is associated with accelerated cognitive decline in people with Alzheimer pathology. Mol Psychiatry. 2020. ↩︎
Yan N, Zhang JJ. The emerging roles of ferroptosis in vascular cognitive impairment. Front Neurosci. 2019. ↩︎